CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer
A Strengthened Leadership Team to Accelerate Growth and Innovation
CorTec GmbH, a pioneer in active implantable technologies and Brain-Computer Interface (BCI) systems, is pleased to announce the appointment of Dr. Frank Desiere as its new Chief Executive Officer (CEO). This significant leadership milestone highlights CorTec’s commitment to driving innovation and growth in the rapidly evolving neurotechnology sector.
CorTec GmbH
The appointment of Dr. Frank Desiere as new CEO marks a pivotal moment for CorTec, leveraging his vast experience to expand its impact in the rapidly growing Neurotech industry. Dr. Oliver Baertl, in the role of COO, will be focusing on leading the component business for active implantable technologies and ensuring operational excellence. CTO Dr. Martin Schuettler, will continue to lead technological advancements and sustained innovation. The strengthened leadership team displays CorTec’s dedication to addressing the dynamic needs of the medical device sector while unlocking new opportunities within the field of Brain-Computer Interfaces.
Introducing Dr. Frank Desiere: A Visionary Leader
Dr. Frank Desiere brings a wealth of experience and a proven track record in the Medical Device and Life Science industry. Holding a PhD in Life Sciences from ETH Zuerich and an MBA from IMD Lausanne, Dr. Desiere has held senior leadership roles at global organizations, including Roche, where he spearheaded business development initiatives and introduced groundbreaking MedTech innovations and digital health solutions. His expertise spans fostering strategic partnerships, driving technology transfer, and leading digital transformation – all central capabilities that align perfectly with CorTec’s vision for shaping the future of Neurotechnology.
“I am thrilled to join CorTec at such an exciting time,” said Dr. Frank Desiere. “The company is at the forefront of active implantable technologies and systems and has a bold vision for the future.
Together with this talented team, we will achieve remarkable breakthroughs, strengthen our position as a technology leader, and unlock new growth opportunities.”
A Unified Vision for the Future
Dr. Oliver Baertl expressed his enthusiasm: “We will be able to further advance our active implantable technologies within the strategic partnership with Heraeus Medevio, while at the same time positioning CorTec in the rapidly growing BCI segment. I am excited to work with Frank, Martin, and the team to drive CorTec’s strategy forward and to empower our partners and customers to realize medical device innovations.”
Commenting on the new leadership structure, Chairman of the Board, Dr. Christoph Mangold adds: “The onboarding of Dr. Frank Desiere as CEO and the composition of a strong leadership team is a clear statement about CorTec’s ambitious plans in the market. This will unlock new strategic opportunities and drive groundbreaking innovation in both the component and BCI segments.”
CorTec is now well positioned to become the Development and Manufacturing partner of choice for implantable technologies and to drive exceptional growth.
Other news from the department people
